Lisocabtagene maraleucel is efficacious at treating R/R chronic lymphocytic leukaemia/small lymphocytic lymphoma

ASCO 2023: Lung cancer research highlights

Pembrolizumab benefits patients with brain metastases

FOLFOX with selective use of 5FUCRT is non-inferior to 5FUCRT for treatment of LARC prior to low anterior resection with TME

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

ASCO's efforts to improve global cancer care through the years

US NCI's global health initiatives at ASCO 2023

The Lancet Commission on Women and Cancer

Advancing breast cancer treatment in Uganda by improving molecular testing

Somatic mutation profile of breast cancer in Uganda

Real-world behavioural restrictional practices of cancer patients

KEYNOTE-716: Longer follow up supports pembrolizumab use in stage IIB/IIC melanoma

Tumour Treating Fields therapy extends OS for mNSCLC after plantinum failure

Primary mediastinal B-cell lymphoma: Radiotherapy superfluous post-chemoimmunotherapy

ASCO 2023: Highlights and analysis

ASCO 2023: Latest in PARP inhibitors in prostate cancer

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine improves PFS in N2-3 nasopharyngeal carcinoma

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC

Axi-cel improves survival in early r/r large B-cell lymphoma

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis

Extended lymph node removal does not benefit patients with clinically localised muscle-invasive bladder cancer

Dostarlimab chemo combination for primary advanced or recurrent endometrial cancer

FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer

Teclistamab for RRMM: Long term follow up data from MajesTEC-1

2L triple metronomic chemo shows more efficacy in comparison to systemic therapy for head and neck cancer

Vaccine-immunotherapy combo for high risk melanoma: New data on distant metastasis-free survival

Next-generation selective RET inhibitor shows initial promise with RET-altered solid tumours

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses in multiple tumour types

Neoadjuvant chemo with mFOLFIRINOX shows survival benefit in locally advanced rectal cancer

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo

Osimertinib after surgery significantly improves survival in resected EGFR-mutated NSCLC

ASCO 2023: Breast cancer research highlights

Ciltacabtagene autoleucel greatly reduces risk of disease progression in lenalidomide-refractory MM

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity

Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice

Sintilimab plus chemo shows promise in high-risk locoregionally-advanced nasopharyngeal carcinoma

ASCO 2023: Head and neck highlights

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to cabozantinib alone in soft tissue sarcoma

Baseline liquid biopsy results in treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC

Real-world behavioural restrictional practices of cancer patients

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment

Pembrolizumab improves OS in firstline treatment for unresectable advanced pleural mesothelioma

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in phase 1

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer

Teclistamab plus talquetamab targeting BCMA and GPRC5D shows promise in RRMM

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT with RT in localised high-risk prostate cancer

Talquetamab plus daratumumab for RRMM: TRIMM-2 update

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer